Скачать с ютуб Cardiac proarrhythmic risk assessment using human iPSC-derived cardiomyocytes - Session 1 в хорошем качестве

Cardiac proarrhythmic risk assessment using human iPSC-derived cardiomyocytes - Session 1

For the past two decades, in vitro human Ether-a-go-go Related Gene (hERG) channel assays and in vivo QT interval measurements have been used to assess proarrhythmic risk during drug development. While this approach has been effective in preventing drugs with cardiac liabilities from reaching the market, it has become evident that some cardiac safe drugs also inhibit the hERG channel or cause QT prolongation. Thus, there is a need for improved accuracy of proarrhythmic risk assessment by reducing the focus on in vitro hERG channel assays and in vivo QT interval measurements.